Ekzon, JSC
Year of establishment2010
Primary activityproduction of pharmaceutical preparations
Products, services description (detailed, indicating CN FEA code)The nomenclature of manufactured products with the indication of the HS code: Tablets (3004900002, 3004500006, 3004900009, 3004320009, 3004490009); Powders (2932190000, 3004900002, 3004900009, 2936270000, 1702305000); Syrups (3004900002, 2106905900); Suspension (3004900002); Spray (3004200002, 3004320009); Solutions (3004900009, 3004900002, 2106905900); Aerosols (3004900009, 3004500002, 3004320009); Capsules (3004490009, 3004900002).
Superior bodyThe Pharmaceutical Holdings Company "Belpharmprom"
General reference and analytical information about the companyEkzon is a modern pharmaceutical company that produces more than a hundred names of medicines and biologically active food additives.
Authorized capital size of the company, thousand $266
Quality of shares issued, pcs1809675
Distribution of shares (by owners)state owned - 99,1964 %, private (individuals) - 0,8036 %
Government body holding sharesMinistry of Health of the Republic of Belarus
Revenue, thousand $11500
Current liquidity ratio3.06
Number of employees as on the month of filling the form, people229
Average salary as on the month of filling the form, BYN2417,7
economic, social effect
Type of investment projectProject in progress
Total volume of investments, thousand $20000
Expected input of an investor, thousand $10000
Project period2024-2030
Investor participation formnew enterprise
Project descriptionThe project involves the establishment of production of finished pharmaceuticals on the basis of JSC “Exon”. The products must meet the license conditions, the requirements of TCP 030-2017 “Good Manufacturing Practices” (GMP), as well as ISO 22000:2005 "Food Safety Management System. Requirements for all organizations in the food production and consumption chain".
The nomenclature of the product to be produced with indication of the CN FEA codeTablets (3004900002, 3004500006, 3004900009, 3004320009, 3004490009); Powders (2932190000, 3004900002, 3004900009, 2936270000, 1702305000)
Annual revenues once fully operational (without VAT, thousand $)15900
Simple pay-back period, yrs11.75
Dymanic pay-back period, yrs15
NPV, thousand $1 359,600
IRR, %6.94
Discount Rate, %5.9
Potential customerSales markets of near and far abroad: CIS countries, EAEU countries, EU countries
Key benefits of the project1) Establishment of the enterprise which comply with all the licensing requirement and the requirements of TKP 030-2017 "Good Manufacturing Practice (GMP)”. 2) Products differentation and the opportunity of export the medicines in EEU and EU countries. 3) Production of high-quality, effective and safe import-substituting medicines. Reducing the using of currency to the buying the similar medicines to import in general for country.
Level of project developmentProject development stage: availability of feasibility study, business plan (development dates – 08.04.2025)
Land area, ha0.45
Land plot purposeto ensure the construction and maintenance of a new workshop for the production of finished pharmaceutical products
GPS coordinates of the land plot52.181493, 25.182751
Vacant space availiability for project implementationyes
Volume of exports from the Republic of Belarus, thousand $2 000